Secondary Stock Offerings
By The Online Investor Staff, updated Fri., Jan. 24, 5:14 PM
| This Slide: #1 of 25 |
Slide #1. Zai Lab Limited — Secondary Offering
Company:
Zai Lab Limited (NASDAQ:ZLAB)
Date announced:
1/22/2020
Shares Offered:
5,500,000
Date of Pricing:
1/22/2020
Price Per Share:
$47.50
Secondary Offering Details:
Zai Lab Limited ("Zai Lab" or the "Company") (NASDAQ: ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, today announced the pricing of its underwritten public offering of 5,500,000 American depositary shares ("ADSs"), each representing one ordinary share of the Company (the "Primary ADS Offering"), at a price of US$47.50 per ADS. In addition, QM11 Limited, a shareholder of the Company, is offering 500,000 ADSs of the Company (the "Secondary ADS Offering" and together with the Primary ADS Offering, the "Offering") at the same price. The Offering is expected to close on January 27, 2020, subject to customary closing conditions. In addition, Zai Lab and QM11 Limited have granted the underwriters a 30-day option to purchase up to an additional 800,000 and 100,000 ADSs, respectively at the public offering price, less underwriting discounts and commissions. Assuming the over-allotment option is not exercised, QM11 Limited will own approximately 13.53% of the Company's share capital immediately following the Offering. Assuming full exercise of the over- allotment option, QM11 Limited will own approximately 12.15% of the Company's share capital immediately following the Offering.
Zai Lab is a biopharmaceutical company based focusing on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. Co.'s drug candidate is niraparib (ZL-2306), an oral, once-daily small molecule PARP 1/2 inhibitor being developed and commercialized by its partner Tesaro, Inc. Tesaro received FDA marketing approval for niraparib as a maintenance treatment for women with recurrent platinum-sensitive epithelial ovarian cancer and, in Apr 2017, commercially launched the product in the United States under the commercial name Zejula.
Open the ZLAB Page at The Online Investor »
|
|||||||||||||||
Open the ZLAB Page at The Online Investor (in a new window) »
List of Secondary Stock Offerings in this Slideshow:
1/7/2020:
Company: Apellis Pharmaceuticals, Inc. (APLS)
Shares Offered: 9,500,000
More: offering details »
1/7/2020:
Company: New York Mortgage Trust, Inc. (NYMT)
Shares Offered: 30,000,000
More: offering details »
1/8/2020:
Company: Mirati Therapeutics, Inc. (MRTX)
Shares Offered: 3,076,924
More: offering details »
1/9/2020:
Company: Aptinyx Inc. (APTX)
Shares Offered: 10,166,666
More: offering details »
1/9/2020:
Company: Kimbell Royalty Partners, LP (KRP)
Shares Offered: 5,000,000
More: offering details »
1/10/2020:
Company: Matinas BioPharma Holdings, Inc. (MTNB)
Shares Offered: 32,260,000
More: offering details »
1/10/2020:
Company: Luckin Coffee Inc. (LK)
Shares Offered: 9,000,000
More: offering details »
1/13/2020:
Company: STAG Industrial, Inc. (STAG)
Shares Offered: 8,750,000
More: offering details »
1/13/2020:
Company: Torchlight Energy Resources Inc (TRCH)
More: offering details »
1/15/2020:
Company: Global Water Resources, Inc. (GWRS)
Shares Offered: 870,000
More: offering details »
1/16/2020:
Company: Aspen Group, Inc. (ASPU)
Shares Offered: 2,100,000
More: offering details »
1/21/2020:
Company: SI-BONE, Inc. (SIBN)
Shares Offered: 4,300,000
More: offering details »
1/21/2020:
Company: Blueprint Medicines Corporation (BPMC)
More: offering details »
1/21/2020:
Company: Adaptimmune Therapeutics plc (ADAP)
Shares Offered: 21,000,000
More: offering details »
1/21/2020:
Company: Applied Therapeutics, Inc. (APLT)
Shares Offered: 1,750,000
More: offering details »
1/21/2020:
Company: Adaptive Biotechnologies Corporation (ADPT)
Shares Offered: 8,000,000
More: offering details »
1/21/2020:
Company: Hutchison China MediTech Limited (HCM)
More: offering details »
1/21/2020:
Company: NanoViricides, Inc. (NNVC)
Shares Offered: 2,500,000
More: offering details »
1/22/2020:
Company: Profound Medical Corp. (PROF)
Shares Offered: 2,950,000
More: offering details »
1/22/2020:
Company: Xenon Pharmaceuticals Inc. (XENE)
Shares Offered: 3,750,000
More: offering details »
1/22/2020:
Company: Trillium Therapeutics Inc. (TRIL)
Shares Offered: 35,731,818
More: offering details »
1/22/2020:
Company: Trillium Therapeutics Inc. (TRIL)
Shares Offered: 1,250,000
More: offering details »
1/22/2020:
Company: Misonix, Inc. (MSON)
Shares Offered: 1,625,000
More: offering details »
1/22/2020:
Company: Autolus Therapeutics plc (AUTL)
Shares Offered: 7,250,000
More: offering details »
1/22/2020:
Company: Zai Lab Limited (ZLAB)
Shares Offered: 5,500,000
More: offering details »
|
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 77th percentile
(ranked higher than approx. 77% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
